Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous house dust mite allergoid immunotherapy versus placebo for moderate to severe allergic rhinitis/rhinoconjunctivitis
2026-526213-28-00Phase 3Authorised
- Sponsor
- Allergopharma
- Start
- Sep 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy comparing Active house dust mite allergoid immunotherapy with Placebo (2 arms). Primary endpoint: Adapted Rhinitis Combined Symptom and Medication Score. Planned start Sep 2026; status: authorised.
02
Drugs
house dust mite allergoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2026-526213-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526213-28-00.